Sanofi American Depositary Receipt (SNY)
Sanofi, Regeneron's Dupixent Meets Late-Stage Urticaria Study Goals
This is the second pivotal late-stage study on SNY/REGN's Dupixent in chronic spontaneous urticaria indication to meet primary and key secondary endpoints.
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is pleased to announce the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Dr. Angel, in collaboration with Telomir's senior management, will look to expedite the pre-clinical and clinical path of Telomir's lead product candidate, Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process.
Why Sanofi Stock Was Robustly Healthy Today
The pharmaceutical-sector mainstay published news about its investigational multiple sclerosis drug. It did well in one trial but was less impressive in two others.
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.
Sanofi MS drug tolebrutinib misses goal in relapsing disease trials
Sanofi's most advanced multiple sclerosis (MS) drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, dimming the prospects for a widely-pursued class of drugs.
Sanofi to invest 1.3 bln euros in new insulin plant in Frankfurt
French drugmaker Sanofi will invest 1.3 billion euros ($1.40 billion) in a new insulin production facility at its existing site in Frankfurt, where it makes insulin brand Lantus, the company said on Thursday.
Sanofi (SNY) Q2 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY ) Q2 2024 Q2 2024 Earnings Conference Call July 25, 2024 8:30 AM ET Company Participants Thomas Kudsk - Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research and Development Brian Foard - Executive Vice President & Head-Specialty Care, Sanofi Thomas Triomphe - Executive Vice President-Vaccines, Sanofi Olivier Charmeil - Executive Vice President, Vaccines Conference Call Participants Graham Parry - BofA Shirley Chang - Barclays Seamus Fernandez - Guggenheim Jo Walton - UBS Tim Anderson - Wolfe Research Luisa Hector - Berenberg Florent Cespedes - Bernstein David Risinger - Leerink Gary Steventon - Exane Ben Jackson - Jefferies Eric Berrigaud - Stifel Peter Verdult - Citi Thomas Kudsk This is Thomas Kudsk Larsen with the IR team. Welcome to the Q2 2024 Conference Call for investors and analyst.
Sanofi (SNY) Q2 Earnings Beat, Sales Miss, 2024 View Raised
Sanofi (SNY) posts mixed quarterly results, beating estimates for earnings while missing the same for sales. It raises its 2024 earnings growth expectations at CER.
Sanofi bumps up full-year forecast after strong Q2 profit
Sanofi's second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year profit compared to a prior forecast of a fall.
Sanofi to invest $437 mln in India global centre, double its workforce
French drugmaker Sanofi plans to invest 400 million euros ($437.24 million) in its global capacity centre (GCC) in India by the end of the decade, as it aims to expand and more than double its workforce over the next two years, a top company executive said on Wednesday.
Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug
Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its experimental drug to treat certain autoimmune skin diseases.
Bpifrance eyes investment in Sanofi's consumer health business
Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi's consumer health unit, Bloomberg News reported on Thursday.
